all the information, none of the junk | biotech • healthcare • life sciences

Curis Gets $3M From Genentech For Ovarian Cancer Trial Initiation

Cambridge, MA-based Curis (NASDAQ: CRIS) said today it will receive a $3 million cash payment from its partner, Genentech (NYSE: DNA). The payment is due because Genentech is starting a clinical trial among patients with ovarian cancer. Researchers will look at 100 patients with the disease, taking either a placebo or GDC-0449, an oral pill made to block the action of the Hedgehog pathway, which is thought to be critical to the survival of cancer cells and their ability to resist chemotherapy.